NNNN

Anbio Biotechnology

$3.80

-6.86%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryGermany

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Source: Yahoo Finance
Q-Score58/ 100
Market Cap$166.8M
P/E26.05
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.32
AI summary

Price & performance

1M-36.8%
3M-64.5%
YTD-88.1%
1Y-79.2%
52-week range—
Beta0.32
Full chart and returns against a benchmark

Q-Score

58/ 100

Quality against peers; 50 is the peer median.

Growth56
Risk34
Performance53
Valuation45
Profitability78
Leverage91
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$8.6M+5.6%
Net income$6.4M+169.9%
Net margin74.1%+45.1 pts
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsApr 7, 2026
Filings, findings and the timeline

Revenue exposure

European Union60%
Asia Pacific18%
Other Regions16%
Largest customer35%
Regions, segments, customers and suppliers

Valuation

NNNNIndustryP/E26.0549.36P/S19.293.73EV/EBITDA27.5723.12P/B5.533.92PEG0.150.15
Dividend yield0.00%
Every valuation metric